Pharmaterials have commissioned and tested its latest addition to X-ray diffraction. Working alongside the previous capability for powder diffraction and single crystal X-ray studies, this new instrument provides very rapid and very sensitive sample handling. Excellent data can be generated with small sample mass and the detection is so good that it can be used to detect and quantify 1% amorphous content in crystalline samples.
Pharmaterials have worked with PANAlytical to develop a 96 well plate transmission system that allows rapid reading of our screening plates as a primary screen for polymorphism.
The facility has been described by PANAlytical staff as a "foremost XRD facility for pharma contract work".
Professor Graham Buckton (Chief Executive of Pharmaterials) said "Pharmaterials continues to develop rapidly in the areas of salt selection, polymorphism screening and physical properties testing and is diversifying its formulation development services. This purchase demonstrates that we intend to remain at the top of the list of service provides for polymorphism screening. Our customers can be sure of the best equipment and the attention of excellent scientists working in a responsive and interactive way with them".